What is IBRX's current stock price?

As of now, IBRX is trading at $5.52, with a daily change of +39.75%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

IBRX Stock Analysis & IQ Rating | ImmunityBio

IBRX IBRX Badge

ImmunityBio

$5.52

+$1.57 | +39.75%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$5.58

MKT CAP

$5.44B

52W Low

$1.83

VOL

$173.94M

P/E Ratio

N/A

AVG VOL

$16.76M

RSI

92.39

TREND

Uptrend

IBRX Stock IQ

Login to see ImmunityBio (IBRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IBRX Target Price

Login to display

Strengths

IBRX Rewards

Upgraded on attractively valued

IBRX Rewards

Earnings are forecast to grow

IBRX Rewards

Investors confidence is positive

IBRX Price Performance

$2.08 (+165.38%)

$2.39 (+130.96%)

$2.38 (+131.93%)

$3.19 (+73.04%)

1year

6month

3month

1month

IBRX Analysts Opinion

IBRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

IBRX Analysts Opinion

IBRX Analysts opinion is positive and also has improved from the past 3 months

IBRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

IBRX Street Sentiment

IBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

IBRX Risk Level

IBRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Low

LOW

HIGH

IBRX Performance Sentiment

Sentiments overview associated with IBRX events and the stock performance.

100%

0%

Positive

Negative

42 out of 42
events present

0 out of 42
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$5.52

Resistance
Price

$1.98

Current Price Range

$5.52

Show methods +

Linked to IBRX

IQ

Close Price

Change

CRSP

4.09

53.51

-1.29%

CLDI

N/A

1.03

-0.96%

Recently Viewed

Close Price

Change

MSGE

Madison Square Garden

59.48

+0.10%

IBRX

ImmunityBio

5.52

+39.75%

STSS

Sharps Technology

2.37

+3.04%

CANG

Cango Inc. American

1.41

-2.76%

FXNC

First National Corporatio

25.69

-0.08%

IBRX Latest Analysis +

Why ImmunityBio Stock Is Skyrocketing Again Today. Key PointsImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials.

Fri Jan 16, 2026

$5.52 | +39.75%

Momentum

ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump. Time to Book Profits?. We recently published 10 Stock With Eye-Popping Gains. 5 Are on Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Thursday. ImmunityBio extended its winning streak to a 10th consecutive day on Thursday soaring 30.79 percent to close at $3.95 apiece as investors loaded portfolios after achieving a 700 percent jump in preliminary [….]

Fri Jan 16, 2026

$5.52 | +39.75%

Activity

Momentum

ImmunityBio Stock Soars On Cancer Trial Progress FDA Timeline. ) stock has surged more than 100% year to date after the upbeat and trial data.The company on Friday said enrollment exceeded internal expectations in its randomized registrational trial in BCG-naïve non-muscle-invasive QUILT-2.005.Enrollment is now over 85% complete with full enrollment of the planned study population anticipated .Based on the current enrollment trajectory ImmunityBio anticipates submitting a biologics license app

Fri Jan 16, 2026

$5.52 | +39.75%

Activity

Earnings

Momentum

ImmunityBio shares climb as bladder cancer trial nears full enrollment BLA submission expected by year-end.

Fri Jan 16, 2026

$5.52 | +39.75%

Momentum

Why PainReform Shares Are Trading Higher By 27%. Here Are 20 Stocks Moving Premarket. Shares of ) rose sharply in .The company announced a name change amid its expansion diversified healthcare and AI-driven energy platforms.PainReform shares jumped 27.4% to $1.02 in the pre-market trading session.Here are some other stocks moving in pre-market trading.ACCL) gained 219.4% to $9.40 in pre-market trading.) rose 72.2% to $2.48 in pre-market trading.) rose 41.3% to $1.08 in pre-market trading after t

Fri Jan 16, 2026

$5.52 | +39.75%

Activity

ImmunityBio Shares Jump On Significant Product Revenue Growth . (RTTNews) - ImmunityBio Inc. (IBRX) a commercial-stage biotechnology company reported preliminary net product revenue growth of 431 percent for the fourth quarter and 700 percent increase for the full year ended on December 31 2025.

Fri Jan 16, 2026

$5.52 | +39.75%

Momentum

Potential

Stock Market Today Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%. ImmunityBio (NASDAQ:IBRX) a cancer and infectious-disease drug developer closed Thursday at $3.95 up 30.79% for the session. The stock jumped after preliminary 2025 results highlighted roughly 700% growth in Anktiva revenue and a quarterly sales beat. Investors are watching on

Thu Jan 15, 2026

$3.95 | +30.79%

Earnings

Momentum

Notable Thursday Option Activity: IBRX VRT NN. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in ImmunityBio Inc (Symbol: IBRX) where a total volume of 77618 contracts has been traded thus far today a contract volume which is representative of approximate

Thu Jan 15, 2026

$3.95 | +30.79%

Momentum

ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug. ) shares are up on Thursday as the company is and sales momentum with a significant increase in preliminary net product revenue.ImmunityBio announced preliminary net product revenue for Anktiva reached for fiscal 2025 reflecting a remarkable 700% increase year-over-year.Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder .For the fourth quarter of 2025 the company reported revenue of about

Thu Jan 15, 2026

$3.95 | +30.79%

Activity

Earnings

Potential

ImmunityBio: Why I Am Upgrading To A Buy For 2026.

Thu Jan 15, 2026

$3.95 | +30.79%

Rating

FAQ About IBRX Stock Insights

What is IBRX current stock price?

What are IBRX stock strengths?

What is IBRX Risk Level?

What is IBRX market cap and volume?

What is IBRX current Stock IQ?

Should I buy IBRX stock right now?

Is IBRX a Strong Buy right now?

What does a 'Strong Buy' rating mean for IBRX?

What does a 'Strong Sell' rating mean for IBRX?

What factors influence IBRX's Stock IQ?

Explore our IBRX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored IBRX Stock Strategies
Effective Risk Management

FIND US ON

Receive our IBRX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

IBRX IBRX Badge

ImmunityBio

Set Alerts

Current Price

$5.52

+$1.57 | +39.75%

52W High

$5.58

MKT CAP

$5.44B

52W Low

$1.83

VOL

$173.94M

P/E Ratio

N/A

AVG VOL

$16.76M

RSI

92.39

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Stock Insights

Strengths

IBRX Rewards

Upgraded on attractively valued

IBRX Rewards

Earnings are forecast to grow

IBRX Rewards

Investors confidence is positive

Linked to IBRX

Symbol

IQ

Close

Change

CRSP

4.09

53.51

-1.29%

CLDI

N/A

1.03

-0.96%

IBRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

IBRX Street Sentiment

IBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

IBRX Risk Level

IBRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Low

LOW

HIGH

IBRX Performance Sentiment

Sentiments overview associated with IBRX events and the stock performance.

100%

0%

Positive

Negative

42 out of 42
events present

0 out of 42
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$5.52

Resistance
Price

$1.98

Current Price Range

$5.52

Show methods +

Latest Analysts Recommendations

Date

Action

Rating

Firm

Dec 17, 2025

Reiterate

Buy

D. Boral Capital

Dec 13, 2025

Reiterate

Buy

Jefferies

Dec 12, 2025

Reiterate

Buy

D. Boral Capital

Nov 14, 2025

Reiterate

Buy

D. Boral Capital

Nov 06, 2025

Reiterate

Buy

D. Boral Capital

IBRX Stock IQ

Login to unlock ImmunityBio (IBRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IBRX Latest Analysis

Why ImmunityBio Stock Is Skyrocketing Again Today. Key PointsImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials.

Fri Jan 16, 2026

$5.52 | +39.75%

Momentum

ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump. Time to Book Profits?. We recently published 10 Stock With Eye-Popping Gains. 5 Are on Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Thursday. ImmunityBio extended its winning streak to a 10th consecutive day on Thursday soaring 30.79 percent to close at $3.95 apiece as investors loaded portfolios after achieving a 700 percent jump in preliminary [….]

Fri Jan 16, 2026

$5.52 | +39.75%

Activity

Momentum

ImmunityBio Stock Soars On Cancer Trial Progress FDA Timeline. ) stock has surged more than 100% year to date after the upbeat and trial data.The company on Friday said enrollment exceeded internal expectations in its randomized registrational trial in BCG-naïve non-muscle-invasive QUILT-2.005.Enrollment is now over 85% complete with full enrollment of the planned study population anticipated .Based on the current enrollment trajectory ImmunityBio anticipates submitting a biologics license app

Fri Jan 16, 2026

$5.52 | +39.75%

Activity

Earnings

Momentum

ImmunityBio shares climb as bladder cancer trial nears full enrollment BLA submission expected by year-end.

Fri Jan 16, 2026

$5.52 | +39.75%

Momentum

Why PainReform Shares Are Trading Higher By 27%. Here Are 20 Stocks Moving Premarket. Shares of ) rose sharply in .The company announced a name change amid its expansion diversified healthcare and AI-driven energy platforms.PainReform shares jumped 27.4% to $1.02 in the pre-market trading session.Here are some other stocks moving in pre-market trading.ACCL) gained 219.4% to $9.40 in pre-market trading.) rose 72.2% to $2.48 in pre-market trading.) rose 41.3% to $1.08 in pre-market trading after t

Fri Jan 16, 2026

$5.52 | +39.75%

Activity

ImmunityBio Shares Jump On Significant Product Revenue Growth . (RTTNews) - ImmunityBio Inc. (IBRX) a commercial-stage biotechnology company reported preliminary net product revenue growth of 431 percent for the fourth quarter and 700 percent increase for the full year ended on December 31 2025.

Fri Jan 16, 2026

$5.52 | +39.75%

Momentum

Potential

Stock Market Today Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%. ImmunityBio (NASDAQ:IBRX) a cancer and infectious-disease drug developer closed Thursday at $3.95 up 30.79% for the session. The stock jumped after preliminary 2025 results highlighted roughly 700% growth in Anktiva revenue and a quarterly sales beat. Investors are watching on

Thu Jan 15, 2026

$3.95 | +30.79%

Earnings

Momentum

Notable Thursday Option Activity: IBRX VRT NN. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in ImmunityBio Inc (Symbol: IBRX) where a total volume of 77618 contracts has been traded thus far today a contract volume which is representative of approximate

Thu Jan 15, 2026

$3.95 | +30.79%

Momentum

ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug. ) shares are up on Thursday as the company is and sales momentum with a significant increase in preliminary net product revenue.ImmunityBio announced preliminary net product revenue for Anktiva reached for fiscal 2025 reflecting a remarkable 700% increase year-over-year.Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder .For the fourth quarter of 2025 the company reported revenue of about

Thu Jan 15, 2026

$3.95 | +30.79%

Activity

Earnings

Potential

ImmunityBio: Why I Am Upgrading To A Buy For 2026.

Thu Jan 15, 2026

$3.95 | +30.79%

Rating

Discover IBRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IBRX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our IBRX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

IBRX Stock trends

IBRX Stock performance

IBRX Stock analysis

IBRX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IBRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IBRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

IBRX Stock Analysis & IQ Rating | ImmunityBio

IBRX Stock IQ

IBRX Target Price

IBRX Analysts Opinion

IBRX Street Sentiment

IBRX Risk Level

IBRX Performance Sentiment

Technical Price Levels

Explore our IBRX Stock insights

Receive our IBRX Daily Alerts

IBRX Street Sentiment

IBRX Risk Level

Technical Price Levels

Latest Analysts Recommendations

Discover IBRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IBRX. We're here to help you make informed investment decisions today.

Receive our IBRX Daily Alerts

IBRX Alerts